Genomic Valley Biotech

Genomic Valley Biotech ROA

Delisted·Sep 16, 2026

The Return on Assets (ROA) of Genomic Valley Biotech (539206.BO) as of Oct 19, 2026 is 8.17 %. In the previous year, Return on Assets (ROA) was 0.35 % — a change of 2,233.46% (higher).

ROA

8.17 %

YoY

2,233.46%

Last updated:

In 2025, Genomic Valley Biotech's return on assets (ROA) was 8.17 %, a 2,233.46% increase from the 0.35 % ROA in the previous year.

The Genomic Valley Biotech ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2022
-0.25 INR
Jan 1, 2023
14.66 INR
Jan 1, 2024
0.35 INR
Jan 1, 2025
8.17 INR
The Genomic Valley Biotech ROA history
YEARROAYoY
8.17 %+2,233.46%
0.35 %-97.61%
14.66 %-6,062.44%
-0.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Valley Biotech Stock analysis

What does Genomic Valley Biotech do? Genomic Valley Biotech Ltd, identified by the ticker symbol 539206.BO and the ISIN code INE574D01010, is an Indian corporate entity established within the biotechnology and life sciences sector. The company maintains its primary operational headquarters in Bahadurgarh, a city located in the state of Haryana, India. This geographical positioning places the firm within a significant industrial and technological hub in northern India, facilitating its business operations and strategic partnerships within the regional ecosystem. The organization entered the public equity markets through an Initial Public Offering that was officially executed on July 10, 2015. This milestone marked a critical transition in the company's corporate history, allowing it to raise capital from public investors and increase its visibility within the financial markets. The listing on the Bombay Stock Exchange under the specified ticker provides a mechanism for public trading and valuation of the company's shares. While specific details regarding its industry classification and sector categorization are not explicitly defined in the available reference data, the company's name and operational focus imply a specialization in genomic technologies and biotechnological solutions. The corporate profile is further accessible through its official digital presence at http://www.genomicvalley.com/, where stakeholders and interested parties can obtain additional information regarding its business activities, corporate governance, and financial performance. As a publicly traded entity, Genomic Valley Biotech Ltd is subject to the regulatory frameworks and disclosure requirements mandated by Indian securities regulators. The company's journey from its foundational establishment to its public listing in 2015 represents a structured growth trajectory aimed at expanding its reach and capabilities in the competitive biotech landscape. Investors and analysts monitoring the Indian market may track the company's performance through its stock ticker, utilizing the ISIN for precise identification in global financial databases. The lack of explicit sector or industry tags in the provided data does not diminish the company's operational identity, which remains anchored in the scientific and technological advancements associated with genomics and biotechnology. The headquarters in Bahadurgarh serves as the central node for administrative, research, and strategic decision-making processes, supporting the company's ongoing initiatives and market engagements. Genomic Valley Biotech is one of the most popular companies on Eulerpool.

ROA Details

Understanding Genomic Valley Biotech's Return on Assets (ROA)

Genomic Valley Biotech's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Genomic Valley Biotech's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Genomic Valley Biotech's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Genomic Valley Biotech’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Genomic Valley Biotech stock

Return on Assets (ROA) of Genomic Valley Biotech is 8.17 % in 2025.

Return on Assets (ROA) of Genomic Valley Biotech changed from 0.35 % to 8.17 %, representing a 2,233.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Genomic Valley Biotech since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Genomic Valley Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genomic Valley Biotech

All Key Metrics — Genomic Valley Biotech